SCHEMBL209392

SCHEMBL209392

COC(=O)c1ccc(-c2ccc(C(C3CCCCC3)C3CCNC3=O)c(OC(F)(F)F)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
EPHX2 P34913 2/20 0.34
NPC1 O15118 1/20 0.34
FAAH O00519 1/20 0.34
CFD P00746 2/20 0.33
SCN9A Q15858 2/20 0.33
HPGDS O60760 1/20 0.33
EPHX1 P07099 1/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
IDH1 O75874 1/20 0.33
PDE4A P27815 3/20 0.33
PDE4B Q07343 3/20 0.33
PDE4C Q08493 3/20 0.33
PDE4D Q08499 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2985336 0.78 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2EPHX2NPC1KMT2A
SCHEMBL4697583 0.78 CDC25B (0.38) ALDH1A1SMN1; SMN2EPHX2NPC1EPHX1
SCHEMBL2990531 0.77 LIPC (0.38) ALDH1A1
SCHEMBL3743305 0.76 NPC1 (0.38) ALDH1A1SMN1; SMN2EPHX2NPC1EPHX1
SCHEMBL209347 0.76 PTPN1 (0.36) MEN1CYP2D6CYP2C9KMT2APDE4A
SCHEMBL2993023 0.72 PDE4D (0.37) ALDH1A1CYP2D6CYP2C9PDE4APDE4B
SCHEMBL208309 0.71 MEN1 (0.35) ALDH1A1SMN1; SMN2NPC1MEN1CYP1A2
SCHEMBL5503358 0.71 PTGS2 (0.33) ALDH1A1
SCHEMBL4062030 0.70 CNR2 (0.41) SMN1; SMN2NPC1MEN1KMT2A
SCHEMBL4062034 0.70 HTT (0.37) ALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP disclosed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US disclosed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US disclosed
EP-2016047-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-01-21 EP disclosed
WO-2007124337-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 88/4885SMN1; SMN2 3587/4885EPHX2 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.